RxDoctor Payments Data

Gillian Ditton, MD

Endocrinology, Diabetes & Metabolism · Boulder, CONPI 1891174801

Payments from drug & device makers

$776in general payments, 2019–2025

Across 30 payments — averaging $25.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mannkind Corporation$150
  • Tandem Diabetes Care, Inc.$136
  • Lilly USA, LLC$112
  • Amgen$86
  • Novo Nordisk$71
  • Insulet Corporation$46
  • plus $175 from 8 others

What the payments were for

  • Food & beverage$74396%
  • Education$324%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$776 in reported general payments places this provider in the 35th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.

See all endocrinology, diabetes & metabolism providers in Colorado

Medicare billing

Part B allowed, 2024
$215,107
Medicare patients
357
Services billed
6,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide362$490,242
TrulicityDulaglutide217$321,799
JardianceEmpagliflozin186$279,765
OzempicSemaglutide151$207,941
RybelsusSemaglutide26$42,205
Tresiba Flextouch U-100Insulin Degludec56$36,849
FarxigaDapagliflozin Propanediol19$28,897
JanuviaSitagliptin Phosphate21$28,226
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog46$21,289
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/711$18,803
LyumjevInsulin Lispro-Aabc16$16,126
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$15,781
Humalog Kwikpen U-100Insulin Lispro55$15,269
Lantus SolostarInsulin Glargine,hum.Rec.Anlog104$13,610
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$12,090

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Insulin Lispro$112$829,681606 claims
Boehringer IngelheimJardiance$21$279,765186 claims
Novo NordiskOzempic, Rybelsus$71$250,147177 claims
AstraZenecaFarxiga$16$28,89719 claims
Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium$42$8,343318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.

Other endocrinology, diabetes & metabolism in Boulder

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →